Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Pathog ; 5(4): e1000392, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19381260

ABSTRACT

The role of CD8 T cells in anti-tuberculosis immunity in humans remains unknown, and studies of CD8 T cell-mediated protection against tuberculosis in mice have yielded controversial results. Unlike mice, humans and nonhuman primates share a number of important features of the immune system that relate directly to the specificity and functions of CD8 T cells, such as the expression of group 1 CD1 proteins that are capable of presenting Mycobacterium tuberculosis lipids antigens and the cytotoxic/bactericidal protein granulysin. Employing a more relevant nonhuman primate model of human tuberculosis, we examined the contribution of BCG- or M. tuberculosis-elicited CD8 T cells to vaccine-induced immunity against tuberculosis. CD8 depletion compromised BCG vaccine-induced immune control of M. tuberculosis replication in the vaccinated rhesus macaques. Depletion of CD8 T cells in BCG-vaccinated rhesus macaques led to a significant decrease in the vaccine-induced immunity against tuberculosis. Consistently, depletion of CD8 T cells in rhesus macaques that had been previously infected with M. tuberculosis and cured by antibiotic therapy also resulted in a loss of anti-tuberculosis immunity upon M. tuberculosis re-infection. The current study demonstrates a major role for CD8 T cells in anti-tuberculosis immunity, and supports the view that CD8 T cells should be included in strategies for development of new tuberculosis vaccines and immunotherapeutics.


Subject(s)
BCG Vaccine/immunology , CD8-Positive T-Lymphocytes/immunology , Tuberculosis/immunology , Animals , CD8 Antigens/immunology , Disease Models, Animal , Humans , Macaca mulatta , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/physiology , Tuberculosis/prevention & control , Vaccination/veterinary
2.
J Virol ; 83(2): 1115-25, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19004937

ABSTRACT

While the smallpox vaccine, Dryvax or Dryvax-derived ACAM2000, holds potential for public immunization against the spread of smallpox by bioterror, there is serious concern about Dryvax-mediated side effects. Here, we report that a single-dose vaccination regimen comprised of Dryvax and an antiviral agent, cidofovir, could reduce vaccinia viral loads after vaccination and significantly control Dryvax vaccination side effects. However, coadministration of cidofovir and Dryvax also reduced vaccine-elicited immune responses of antibody and T effector cells despite the fact that the reduced priming could be boosted as a recall response after monkeypox virus challenge. Evaluations of four different aspects of vaccine efficacy showed that coadministration of cidofovir and Dryvax compromised the Dryvax-induced immunity against monkeypox, although the covaccinated monkeys exhibited measurable protection against monkeypox compared to that of naïve controls. Thus, the single-dose coadministration of cidofovir and Dryvax effectively controlled vaccination side effects but significantly compromised vaccine-elicited immune responses and vaccine-induced immunity to monkeypox.


Subject(s)
Antiviral Agents/administration & dosage , Cytosine/analogs & derivatives , Mpox (monkeypox)/prevention & control , Organophosphonates/administration & dosage , Smallpox Vaccine/adverse effects , Smallpox Vaccine/immunology , Vaccinia/prevention & control , Animals , Antibodies, Viral/immunology , Cidofovir , Cytosine/administration & dosage , Drug Incompatibility , Macaca fascicularis , Smallpox Vaccine/administration & dosage , T-Lymphocytes/immunology
3.
J Infect Dis ; 195(1): 55-69, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17152009

ABSTRACT

Gene networks of protective lymphocytes after immune activation with live attenuated vaccines remain poorly characterized. Because Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine can confer protection against fatal forms of tuberculosis in humans and monkeys, we made use of macaque models to optimally study immune gene networks after BCG vaccination/infection. We first established and validated a large-scale real-time quantitation system and then used it to measure expression levels of 138 immune genes after BCG vaccination/infection of rhesus macaques. Systemic BCG vaccination induced up to 600-fold increases in expression of 78 immune genes among the 138 genes tested at the time when BCG-elicited T cell responses and immunity were apparent. These up-regulated transcripts constituted multiple gene networks that were linked to various aspects of immune function. Surprisingly, the up-regulation of most of these immune genes in the gene networks occurred at 1 week and was sustained at > or = 6 weeks after BCG vaccination/infection. Although early activation of immune gene networks was an immune correlate of anti-BCG immunity, prolonged up-regulation of these networks coincided with the development of vaccine-elicited T cell responses after BCG vaccination/infection. These findings provide molecular evidence suggesting that the BCG-induced gene networks may represent global transcriptomes and proteomes underlying the development of T cell responses and, ultimately, immunity to mycobacteria.


Subject(s)
BCG Vaccine/immunology , Immunity, Cellular , Tuberculosis/prevention & control , Animals , Antibodies, Bacterial/biosynthesis , Antigens, Bacterial/administration & dosage , BCG Vaccine/administration & dosage , Macaca , Mycobacterium Infections/immunology , Mycobacterium Infections/prevention & control , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/immunology , Tuberculosis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...